There are currently 106 clinical trials in Bellevue, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwest Clinical Research Center, Overlake Medical Center, Overlake Hospital Medical Center and Swedish Cancer Institute-Eastside Oncology Hematology. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/15/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Migraine
Register for Updates
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
NCT06074562
Recruiting
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/15/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Chronic Migraine
Register for Updates
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731
Recruiting
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
04/15/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Alzheimer's Disease
Register for Updates
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Obesity, Overweight, Osteo Arthritis Knee
Register for Updates
Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426
Recruiting
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2024
Locations: Neumora Investigator Site, Bellevue, Washington
Conditions: Major Depressive Disorder
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Overlake Medical Center, Bellevue, Washington
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055
Recruiting
To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use - and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Washington Center for Pain Management, Bellevue, Washington
Conditions: Pain
Register for Updates
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141
Recruiting
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Overlake Medical Center, Bellevue, Washington
Conditions: Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
Register for Updates
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT05647265
Recruiting
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients wit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Overlake Medical Center, Bellevue, Washington
Conditions: Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Register for Updates
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Overlake Medical Center, Bellevue, Washington
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Overlake Medical Center, Bellevue, Washington
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Register for Updates